biomedvc.com

NEWS

8.1.2026

Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development

Press Release
7.1.2026

Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical

Press Release
15.10.2025

Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

Press Release
28.08.2025

TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation

Press Release
26.08.2025

Scenic Enters License and Research Agreement with Alnylam

Press Release
13.05.2025

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical programs of innovative therapies in lysosomal storage disorders

Press Release
07.05.2025

cenic Biotech Announces Nature Publication on the Discovery of Drug Target PLA2G15, a Modifier in Lysosomal Disease

Press Release
06.05.2025

Topas Therapeutics’ TPM502 Achieves Gluten- specific Tolerance In duction, Positive Safety Profile i n Phase 2a Trial i n Celiac Disease Patients

Press Release
09.01.2025

TRiCares Announces First Topaz Implantations in US Early Feasibility Study

Press Release
15.10.2024

Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease

Press Release
2024-09-24

TRiCares Announces F i r s t Topaz Implantation in EU Pivotal Study

Press Release
2022-12-06

TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation

Press Release
2022-10-23

Allecra Therapeutics Announces Late-breaker Presentation of Phase 3 ALLIUM Trial with Cefepime-Enmetazobactam in cUTIs

Press Release
2022-10-13

Inotrem announces positive outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide

Press Release
2022-09-12

Precirix enters into collaboration with Eckert & Ziegler for the development of its 68Ga-based compounds

Press Release
2022-08-30

TRiCares Announces First Successful Implantation

Press Release
03.05.2022

Tubulis Closes EUR 60m Series B to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Press Release
2022-04-06

Cardior Appoints Dr. Russell Greig as Independent Chairman of the Board

Press Release
2022-03-22

Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease

Press Release
2022-02-15

Topas Therapeutics Appoints Cristi na de Mi n, M.D. as Chief Medical Officer

Press Release
2022-02-14

Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders

Press Release
25.06.2017

Ian Crosbie joins Sequana Medical AG as Chief Financial Officer

25.06.2017

Cell Medica acquires Delenex Therapeutics

25.06.2017

Vaximm appoints Pharmaceutical Industry Veteran Dr. Jarl Ulf Jungnelius as Chief Medical Officer

25.06.2017

Former Bayer and Pharmacia Senior Executive Rolf. A. Classon joins the Sequana Medical AG Board as Chairman

25.06.2017

Jörn Aldag appointed CEO of Hookipa Biotech

25.06.2017

Aleva Neurotherapeutics raises USD 18 million in Series C Financing Round

25.06.2017

BioMedPartners strengthens management team

25.06.2017

Vaximm ernennt den Pharmaindustrie-Veteran Dr. Jarl Ulf Jungnelius zum Chief Medical Officer

23.06.2017

Inotrem successfully completes its first Ph I clinical trial with MOTREMTM

25.06.2017

Occlutech GmbH receives 2016 European Minimally - Invasive Structural Heart Devices Product Line Strategy Leadership Award from Frost & Sullivan

25.06.2017

Anergis SA closes CHF 5 million Financing Round Extension

25.06.2017

Polyphor announces $3 million Award from Cystic Fibrosis Foundation Therapeutics

25.06.2017

BC Platforms and Microsoft to Provide expanded Genomic Data Management Solutions in the Cloud

25.06.2017

Aleva Neurotherapeutics and Greatbatch, Inc. Collaborate on Next-Generation Device for Deep Brain Stimulation (DBS)

25.06.2017

Genkyotex's GKT137831 Granted Orphan Drug Designation in the US and EU

25.06.2017

VAXIMM appoints Dr. Matthias Schroff as Chief Executive Officer

23.06.2017

Anergis completes Patient Recruitment in Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT

23.06.2017

Spineart secured a EUR 30 million investment from Gimv

23.06.2017

Vaximm Announces Collaboration with Merck KGaA and Pfizer

18.10.2017

Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors

04.10.2017

Aleva Neurotherapeutics Raises USD 13 Million in Series D Financing Round

11.09.2017

BioMedPartners Co-Leads Investment in AMAL Therapeutics of First EUR 8 Million Tranche of Series B

22.06.2017

Miracor Announces Positive Interim Clinical Data with Novel PiCSO® Impulse System for AMI Patients

04.10.2017

VAXIMM Receives Orphan Designation for the EU and the US for Oral T-cell Immunotherapy VXM01 to Treat Glioma

23.06.2017

VAXIMM Announces Data from Ph I Trial in Glioblastoma with Oral T-cell Immunotherapy VXM01 to be Presented at ASCO 2017 Annual Meeting

22.06.2017

Kalina Scott appointed new CFO of Polyphor

23.06.2017

Polyphor announces successful end of phase II meeting with FDA for Murepavadin in nosocomial pneumonia

23.06.2017

BioMedPartners, with Its BioMedInvest III Fund, Invests in EUR 15 Million Series A Round of Cardiovascular Start-Up Cardior Pharmaceuticals

23.06.2017

Humedics Announces Appointment of Karsten Damgaard-Iversen as CEO

23.06.2017

BC Platforms Closes USD 10 million Series B Financing to accelerate knowledge platform development

23.06.2017

BioMedInvest sells its stake of idiag AG to a private investor

23.06.2017

Giacomo di Nepi Appointed New CEO of Polyphor

23.06.2017

Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech

23.06.2017

Polyphor Announces Closing of CHF 40 Million Private Financing Round

23.06.2017

Symetis SA and Boston Scientific Reach USD 435 Million Purchase Agreement

23.06.2017

Debra Baker Appointed New CMDO of Polyphor

23.06.2017

Dr. Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech

23.06.2017

BioMedPartners Raise CHF 75 Million in First Closing of Their New Healthcare Venture Fund

23.06.2017

Swiss Medtech Symetis Broadens Presence in Structural Heart with Acquisition of U.S. Mitral Valve Device Company Middle Peak Medical

25.06.2017

ImevaX strengthens executive management team and supervisory board with key appointments

23.06.2017

Anergis SA appoints Dr. Klaus Schollmeier as new Chairman of the Board of Directors

23.06.2017

Genticel and Genkyotex Announce Intention to Enter into Strategic Combination

23.06.2017

Miracor receives additional funding in Series-C closing to expand clinical and commercial activities with the PICSO® Impulse System

25.06.2017

Curetis IPO priced at EUR 10.00 per share; raises EUR 40 million

26.06.2017

BioMedInvest AG II joins Humedics Series C financing round

25.06.2017

Ayoxxa is Member of the International EYE-RISK Consortium

26.06.2017

Übernahme der Degradable Solutions AG durch die Sunstar Suisse SA

26.06.2017

Evolva and Cargill in deal to co-develop Steviol Glycosides

26.06.2017

Evolva to raise up to CHF 31.3 million

26.06.2017

Spinelab announces Exclusive Distribution Agreement with Biomet for Spain and Portugal

26.06.2017

Sias AG acquires Xiril AG

26.06.2017

Spinelab raises CHF 4.7 million in Series C financing round

26.06.2017

Okairos initiates Phase I/II clinical trial for potential first-in-class hepatitis C vaccine

26.06.2017

Sequana Medical’s ALFApump® System receives reimbursement in Germany

26.06.2017

SuppreMol with positive interim Phase Ib/IIa results on SM101 in ITP trials

26.06.2017

Symetis receives CE Mark for its ACURATE TA transapical TAVI system

26.06.2017

GSK acquires Okairos AG for EUR 250 Mio. in cash

26.06.2017

Okairòs AG strengthens its board of directors and management team

26.06.2017

Series A financing round of Aleva Neurotherapeutics SA

26.06.2017

Sequana Medical (former NovaShunt AG) receives CE Mark Approval for the ALFApumpTM System

26.06.2017

Spinelab presents its spine implant system Elaspine™

26.06.2017

Series A financing round of Anergis SA

26.06.2017

Series B financing round of NovaShunt AG

26.06.2017

SuppreMol completes successful Pre-IND Meeting with FDA

27.06.2017

Erfolgreiches pre-IND-Meeting mit FDA durch SuppreMol zur Durchführung Klinischer Studien

27.09.2017

Anergis Announces Top Line Results from Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT

26.06.2017

SuppreMol raises EUR 9.5 million in Extended Series D Financing Round

26.06.2017

Polyphor attracts senior Pharma professionals to strengthen its Board of Directors

25.06.2017

Aleva awarded grant from the Michael J. Fox foundation

26.06.2017

EyeSense Attracts Lee’s Pharmaceutical Holdings as Strategic Investor

25.06.2017

Aleva appoints Dr. Philippe Dro to its Board of Directors

25.06.2017

Genkyotex announces top-line results of Ph II clinical program

25.06.2017

Baxter's Bioscience Business acquires biopharmaceutical company SuppreMol GmbH

25.06.2017

ImevaX welcomes KfW to investor syndicate in second closing of Series A financing

25.06.2017

BioMedInvest AG II leads Series B+ financing round of Miracor Medical Systems GmbH

25.06.2017

BioMedInvest AG II co-leads Series D financing round of Genkyotex S.A.

26.01.2018

Polyphor: Global No. 2 in the 2018 Antimicrobial Resistance Benchmark announced at World Economic Forum

26.06.2017

Anergis starts Ph II dose ranging trial with Birch Pollen Allergy Vaccine AllerT

26.06.2017

Ayoxxa Biosystems extends Series B

26.06.2017

ImevaX secures EUR 7.5 million in Series A financing to develop highly specific vaccine against Helicobacter pylori infections

26.06.2017

Polyphor achieves first milestone in macrocycle drug discovery collaboration with Boehringer Ingelheim

26.06.2017

Symetis SA receives CE Mark approval for ACURATE neo

26.06.2017

BioMedInvest AG II co-leads Series C financing of Sequana Medical AG

26.06.2017

BioMedInvest AG II joins Inotrem S.A.'s Series A Closing

26.06.2017

BioMedInvest AG II portfolio company Activaero acquired by Vectura Group

26.06.2017

Anergis SA closes financing round totaling CHF 8 million

26.06.2017

Polyphor and Roche join efforts to combat multidrug-resistant bacterial infections

26.06.2017

Hookipa Biotech closes EUR 20 Mio. in Series B Financing

26.06.2017

BioMedInvest AG II joins Middle Peak's Series A in Second Closing

26.06.2017

Anergis receives Swiss Life Sciences Prize

04.01.2018

Miracor Medical raises EUR 25 Million

25.09.2018

VAXIMM Announces Regional Development and Commercialization Agreement with China Medical System Holdings

15.02.2018

Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic in Resistant Infections

15.12.2023

Noema Pharma Appoints Ilise Lombardo as CEO

Press Release
21.12.2023

Precirix - CAM-H2 production at Evergreen marks the expansion of Precirix’ clinical trial to the US

21.12.2023

ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002

Press Release
21.12.2023

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Press Release Press Release
21.12.2023

Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round

Press Release
21.12.2023

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA

21.12.2023

Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease

Press Release
21.12.2023

ImmunOs Therapeutics Receives Regulatory Approval for First-In- Human Trial of IOS-1002

Press Release
21.12.2023

Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA- Based Lead Candidate CDR132L in Heart Failure Patients Post- Myocardial Infarction

Press Release
20.04.2023

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

21.12.2023

Inotrem receives approval to expand nangibotide clinical trial in critically ill COVID-19 patients and receive additional public funding of €45 million

Press Release
20.04.2023

ALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1

04.10.2022

TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation

Press Release
04.10.2022

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

Press Release
07.06.2022

BioMedInvest-III portfolio company ImmunOs raises a USD 74 million Series B financing round

Press Release
16.03.2022

Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals

Press Release
10.03.2022

Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases

Press Release
15.02.2022

AMAL Therapeutics Succeeds in Advancing First-in-Cass Triple Combination Immunotherapy to Studies in Patients with Colorectal Cancer

Press Release
15.02.2022

Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer

Press Release
15.02.2022

Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage

Press Release
21.12.2023

Topas Therapeutics In itiates Phase 2a Cli n ical Trial for TPM502 i n Celiac Disease; Appoints Chief Busi ness Officer an d Chief Operati ng Officer

Press Release
21.12.2023

TOLREMO therapeutics Completes USD 39 Million Series A Financing Round with Strategic Investment from Pierre Fabre Invest

23.09.2021

Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts

05.08.2024

TRiCares Raises $50m in Series D Financing to Support Upcoming Clinical Milestones

Press Release
30.10.2025

TOLREMO therapeutics Welcomes Multiple Myeloma Leader Kenneth C. Anderson to its Scientific Advisory Board

Press Release
30.10.2025

Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M)

Press Release
17.10.2025

TOLREMO therapeutics Completes First In Human Dose Escalation for TT125-802 and Presents Solid Tumor Monotherapy Results at ESMO 2025

Press Release
11.09.2025

Scenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic Diseases

Press Release
04.09.2025

Scenic Biotech Publishes Novel Drug Target for Mitochondrial and Cardiac Disease in Nature

Press Release
18.06.2025

TOLREMO therapeutics Announces Strengthening of Leadership: Alessandra Cesano Joins Board of Directors, Florian D. Vogl Appointed Chief Medical Officer

Press Release
18.06.2025

TOLREMO therapeutics Announces TT125-802 is the First CBP/p300 Bromodomain Inhibitor to Show Clinical Activity in Solid Tumors

Press Release
19.09.2024

ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base

Press Release
30.04.2024

Scenic Biotech enters into Research Collaboration with Bristol Myers Squibb

Press Release
21.12.2023

Precirix announces key leadership appointments

Press Release
25.03.2024

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

Press Release
18.03.2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Press Release
04.03.2024

Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections

Press Release
13.05.2025

ALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1

Press Release
21.12.2023

Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled

Press Release
21.12.2023

Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma

Press Release
21.12.2023

TOLREMO Treats First Patient in Phase I Trial with TT125-802, a Novel Therapeutic Agent to Overcome Transcriptional Cancer Drug Resistance

Press Release
21.12.2023

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Press Release
21.12.2023

Precirix appoints leading radiopharmaceutical and oncology experts to newly formed Scientific Advisory Board

Press Release
04.01.2022

Alentis Therapeutics starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis

Press Release
01.09.2021

ImmunOs Therapeutics Appoints Jeffrey Abbey as Chief Operating Officer, Establishes Clinical Advisory Board

04.12.2017

BioMedPartners Co-Invests in Allecra Therapeutics’ Staged Financing to Take Company Through to End of Phase 3

25.09.2018

BioMedPartners Leads CHF 9 Million Series A Investment in TOLREMO Therapeutics

10.02.2020

Aleva Neurotherapeutics Receives CE Mark for its Directional Deep Brain Stimulation System

16.07.2019

First Exit for BioMedInvest III: Boehringer Ingelheim Acquires AMAL Therapeutics

12.09.2019

Inotrem Raises €39M in Series B Financing

01.05.2019

BioMedPartners Co-Leads CHF 12.5 Million Series A Investment in ALENTIS Therapeutics

26.02.2019

HOOKIPA Pharma Raises $37.4 million (€33.2 million) in Series D Financing

19.11.2018

BioMedPartners co-leads EUR 37M Series A investment in Camel-IDS

23.04.2019

HOOKIPA Pharma Announces Pricing of Initial Public Offering

12.11.2018

AMAL Therapeutics finalises € 29 million Series B round

11.10.2018

What’s the Best Strategy for Swiss Biotech Start-Ups? Interview with BioMedPartners' Markus Hosang

06.02.2020

Cardior Pharmaceuticals Publishes Pre-Clincal Study Results for Heart Failure in Nature Communications

04.06.2018

BioMedPartners Co-Invests in TRiCares' €22 Million Series B Financing Round

05.06.2018

Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

22.05.2018

Polyphor prices its IPO at CHF 38 per share and lists on SIX Swiss Exchange

28.05.2018

Miracor Medical announces new publication: PiCSO therapy reduces infarct size in STEMI patients.

28.05.2018

VAXIMM Announces Final Results from Phase I Trial in Recurrent Glioblastoma with Oral T-cell Immunotherapy VXM01

28.05.2018

BC Platforms Partners with Google Cloud to offer Transformational and Scalable Genomic Solutions Worldwide

01.03.2018

BioMedPartners Close Their New Healthcare Venture Fund BioMedInvest III at CHF 100 Million

23.04.2018

Polyphor announces plans for IPO at SIX Swiss Exchange in Q2/2018

16.04.2018

BC Platforms Appoints Richard Kivel as Chairman to Accelerate Global Growth

15.01.2020

BC Platforms Closes $15 million Series C Financing and Signs Partnership with IQVIA

10.02.2020

BioMedPartners Co-Invests in Azafaros' €25 Million Series A Financing Round

25.08.2021

Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

22.12.2020

Allecra Therapeutics & Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/ enmatazobactam for Greater China

29.07.2021

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$48 Million) in this Round

06.07.2021

TRiCares Announces Successful First in Human Implantations of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System

28.06.2021

Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer

15.06.2021

Alentis Therapeutics Raises USD 67 Million in Series B Financing

11.05.2021

Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board

20.04.2021

Tubulis appoints Günter Fingerle - Rowson as Chief Medical Officer to lead the clinical development of its new generation of ADCs

06.04.2021

Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorders

25.03.2021

Inotrem bolsters leadership team with the appointment of Sven Zimmermann as new CEO

12.01.2021

Dr. Niva Almaula joins Precirix as Chief Business Officer

03.12.2020

BioMed Swiss Partner in strong international Syndicate raising CHF 54 Mio Series A for Roche Spin-Off Rare Disease Neuroscience Company Noema

10.12.2019

BioMedPartners Co-Leads CHF 15M Series A Investment in ImmunOs Therapeutics

16.12.2020

Prof. Baumert of BioMedPartners Company Alentis awarded the most prestigious award of the French Academy of Science

20.10.2020

Topas Therapeutics Raises € 22 Million in Series B Financing

03.09.2020

Miracor Medical raises € 24 Million Series E Financing Round

22.09.2020

Camel-IDS enters next stage with name change to PRECIRIX® and IND approval for CAM-H2 Phase I/II study

30.07.2020

Alentis Therapeutics Names Roberto Iacone CEO Business Wire

21.07.2020

Tubulis Raises €10.7 Million Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

23.06.2020

Miracor Medical's PiCS System receives CE Mark

11.06.2020

Azafaros B.V. incorporates a Swiss subsidiary in Basel and expands its management team with three experienced pharma executives

11.06.2020

Tolremo receives additional CHF 4.7 Million in Series A financing, bringing total Series A round to CHF 13.7 Million

13.12.2017

Hookipa Biotech Raises €50 million in an Oversubscribed Round C Financing